These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31240499)

  • 41. Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study.
    Drobinski PJ; Bay-Jensen AC; Karsdal MA; Sardar S; Siebuhr AS
    Arthritis Res Ther; 2021 Jan; 23(1):13. PubMed ID: 33413588
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
    Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
    Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.
    Huizinga TW; Conaghan PG; Martin-Mola E; Schett G; Amital H; Xavier RM; Troum O; Aassi M; Bernasconi C; Dougados M
    Ann Rheum Dis; 2015 Jan; 74(1):35-43. PubMed ID: 25169728
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial.
    Sanmarti R; Veale DJ; Martin-Mola E; Escudero-Contreras A; González C; Ercole L; Alonso R; Fonseca JE;
    Arthritis Rheumatol; 2019 Oct; 71(10):1616-1625. PubMed ID: 31087542
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review.
    Besada E
    Patient Prefer Adherence; 2014; 8():1051-9. PubMed ID: 25120354
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Two-year efficacy of tocilizumab in patients with active rheumatoid arthritis in clinical practice.
    Notario Ferreira I; Ferrer González MA; Morales Garrido P; González Utrilla A; García Sanchez A; Soto Pino MJ; Suero Rosario E; Caro Hernández C; Añón Oñate I; Pérez Albaladejo L; Cáliz Cáliz R
    Reumatol Clin; 2017; 13(2):78-84. PubMed ID: 27174398
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    McLaughlin M; Östör A
    Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Aftermath of Tapering Tocilizumab After Achieving Treatment Target in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study.
    Park JW; Kim MJ; Kim HA; Kim JH; Lee EB; Shin K
    Front Med (Lausanne); 2022; 9():839206. PubMed ID: 35211491
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.
    Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge EM; Pavelka K; Nordström DC; Canhão H; Tomšič M; van Vollenhoven R; Gabay C
    Rheumatology (Oxford); 2016 Feb; 55(2):230-6. PubMed ID: 26316581
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect on Costs and Quality-adjusted Life-years of Treat-to-target Treatment Strategies Initiating Methotrexate, or Tocilizumab, or Their Combination in Early Rheumatoid Arthritis.
    Verhoeven MMA; Tekstra J; van Laar JM; Pethö-Schramm A; Borm MEA; Bijlsma JWJ; Jacobs JWG; Lafeber FPJG; Welsing PMJ
    J Rheumatol; 2021 Apr; 48(4):495-503. PubMed ID: 32739893
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neutrophil count reduction 1 month after initiating tocilizumab can predict clinical remission within 1 year in rheumatoid arthritis patients.
    Nakajima T; Watanabe R; Hashimoto M; Murata K; Murakami K; Tanaka M; Ito H; Yamamoto W; Kitagori K; Akizuki S; Nakashima R; Yoshifuji H; Ohmura K; Matsuda S; Morinobu A
    Rheumatol Int; 2022 Nov; 42(11):1983-1991. PubMed ID: 34241658
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
    Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
    Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
    Burmester GR; Choy E; Kivitz A; Ogata A; Bao M; Nomura A; Lacey S; Pei J; Reiss W; Pethoe-Schramm A; Mallalieu NL; Wallace T; Michalska M; Birnboeck H; Stubenrauch K; Genovese MC
    Ann Rheum Dis; 2017 Jun; 76(6):1078-1085. PubMed ID: 28007755
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis.
    Soubrier M; Pei J; Durand F; Gullestad L; John A
    Rheumatol Ther; 2017 Jun; 4(1):133-149. PubMed ID: 27900570
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: New evidence from real-world data.
    Paul SK; Montvida O; Best JH; Gale S; Pethoe-Schramm A; Sarsour K
    Semin Arthritis Rheum; 2018 Feb; 47(4):478-484. PubMed ID: 28947313
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction.
    Smolen JS; Avila JC; Aletaha D
    Ann Rheum Dis; 2012 May; 71(5):687-93. PubMed ID: 22121130
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
    Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
    Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study.
    Flipo RM; Maillefert JF; Chazerain P; Idier I; Coudert M; Tebib J
    RMD Open; 2017; 3(1):e000340. PubMed ID: 28123778
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry.
    Pappas DA; Kremer JM; Griffith J; Reed G; Salim B; Karki C; Garg V
    Rheumatol Ther; 2017 Dec; 4(2):375-389. PubMed ID: 28840531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.